The University of Texas M. D. Anderson Cancer Center SPORE in Melanoma

描述(申请人提供)：德克萨斯大学M.D.安德森癌症中心的这项皮肤癌更新孢子竞争的总体目标是促进在黑色素瘤预防、检测和治疗方面的创新转化研究，从而消除这种疾病。该孢子旨在通过召集一群才华横溢的科学家来实现这一目标，这些科学家致力于将黑色素瘤的特定发现从实验室转化为临床，以及从临床转化为实验室。德克萨斯大学安德森癌症中心将消除黑色素瘤作为健康风险的优先事项，为此，于1998年建立了黑色素瘤多学科研究计划，以支持跨越传统行政边界的培训和研究。该计划提供了资源和结构，使我们在2004年成功地资助了第一个完全用于黑色素瘤的孢子，这使我们能够进一步推进几个翻译主题，并为这次续签申请提供基础。这个黑色素瘤的孢子提出了五个翻译项目，其中四个包括连续几年开始的治疗方案，并利用了我们庞大的黑色素瘤患者群体。这五个项目和四个方案由三个核心提供服务：行政(A)、信息学、组织资源和病理学(B)以及生物静态和生物信息学(C)。发展研究计划(DRP)和职业发展计划(CDP)继续作为我们孢子的成功方面，因为每个新项目都至少有一名DRP/CDP获奖者作为新的联合领导者。拟议的五个项目涉及激活Toll样受体(TLR)以进行特定免疫刺激(#1)；抑制pSTAT3以控制集中在中枢神经系统的黑色素瘤转移(#2)；阐明黑色素瘤JNOS相关炎症以制定预后标志和靶向治疗(#3)；使用纳米脂质体技术系统地输送血管生成抑制物(#4)；以及免疫和炎症的遗传机制，以生成综合风险模型，作为基于人群的项目的一部分(#5)。通过这项研究计划，并在德克萨斯大学安德森癌症中心的全力支持下，该孢子旨在对患者黑色素瘤的预防、检测和治疗产生重大影响。

DESCRIPTION (provided by applicant): The overall goal of this competing renewal SPORE in skin Cancer from The University of Texas M.D. Anderson Cancer Center is to facilitate innovative translational research in the prevention, detection and treatment of melanoma leading to the elimination of the disease. This SPORE aims to achieve this goal by assembling a talented group of scientists who are committed to the translation of melanoma-specific findings from the laboratory to the clinic as well as from the clinic to the laboratory. The University of Texas M.D. Anderson Cancer Center has prioritized the elimination of melanoma as a health risk, and to this end established in 1998, a Multidisciplinary Research Program in Melanoma to support training and research across traditional administrative boundaries. The program provided resources and a structure that led to our successful funding in 2004 for the first SPORE dedicated entirely to Melanoma, which allowed us to further advance along several translational themes and provide a basis for this renewal application. This SPORE in Melanoma proposes five translational projects, four of which included treatment protocols to begin in successive years and takes advantage of our large melanoma patient population. The five projects and four protocols are served by three cores: Administrative (A), Informatics, Tissue Resource, and Pathology (B), and Biostatics and Bioinformatics (C). The Developmental Research Program (DRP) and Career Development Program (CDP) continue as successful aspects of our SPORE as each new project incorporates at least one DRP/CDP awardee as a new Co-Leader. The five proposed projects address activation of Toll-Like Receptors (TLR) for specific immune stimulation (#1); inhibition of pSTAT3 for control of melanoma metastasis focused in the CNS (#2); elucidation of melanoma JNOS-related inflammation for development of a prognostic signature as well as a target therapy (#3); systemic deliver of angiogenesis inhibitors using nanoliposomal technology (#4); and genetic mechanisms of immunity and inflammation to generate an integrated risk model as part of a population based project (#5). Through this research program and with the full support of The University of Texas M.D. Anderson Cancer Center, this SPORE aims to make a significant impact toward the prevention, detection, and treatment of melanoma in patients.